Memantine: procognitive and antinegative effects in mental illness (a literature review)
https://doi.org/10.14412/2074-2711-2020-3-117-122
Abstract
According to the instruction approved in the Russian Federation, Akatinol Memantine is indicated for the treatment of all types of dementia regardless of its severity. In addition, data are being accumulated on the use of memantine in a wide range of mental disorders, including schizophrenia, bipolar affective disorder, recurrent depression, obsessive-compulsive disorder, etc.
This review is devoted to the analysis of an update on adjuvant therapy with memantine for the above mental disorders. It discusses the precogni-tive and antinegative effects of the drug in schizophrenia on the basis of the data of meta-analyses and double-blind, placebo-controlled studies.
About the Authors
D. V. Romanov
Department of Psychiatry and Psychosomatics, N.V. Sklifosofsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; Department for Borderline Mental Pathology and Psychosomatic Disorders, Mental Health Research Center
Russian Federation
Competing Interests: There are no conflicts of interest.
Russian Federation
Dmitry Vladimirovich Romanov.
11, Rossolimo St., Build. 1, Moscow 119021; 34, Kashirskoe Shosse, Moscow 115230.
Competing Interests: There are no conflicts of interest.
P. G. Yuzbashyan
Department of Psychiatry and Psychosomatics, N.V. Sklifosofsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests: There are no conflicts of interest.
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021.
Competing Interests: There are no conflicts of interest.
References
1. Alzheimer's Association encouraged by FDA approval of memantine, October 17, 2003. 5 EMEA (European Medicines Agency), EPAR, Axura, July 4, 2002 http://www.eudra.org/humandocs/humans/epar/axura/axura.htm.
2. Laver K, Cumming RG, Dyer SM, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016 Mar 21;204(5): 191-3. doi: 10.5694/mja15.01339.
3. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 2015 Jun;22(6):889-98. doi: 10.1111/ene.12707. Epub 2015 Mar 25.
4. National Institute for Health and Care Excellence (Great Britain). Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers.; 2018. http://www.ncbi.nlm.nih.gov/books/NBK513207/
5. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev. 2003;(3):CD003154. doi: 10.1002/14651858.CD003154.
6. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6.
7. Johnson J, Kotermanski S. Mechanism of action of memantine. Curr Opin Pharmacol. 2006 Feb;6(1):61-7. doi: 10.1016/j.coph.2005.09.007. Epub 2005 Dec 20.
8. Chen H, Pellegrini J, Aggarwal S, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992 Nov;12(11): 4427-36. doi: 10.1523/JNEUROSCI.12-11-04427.1992.
9. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. 2004 Dec;6(6 Suppl):S61-74. doi: 10.3233/jad-2004-6s610.
10. Moriguchi S, Ishizuka T, Yabuki Y, et al. Blockade of the KATP channel Kir6.2 by memantine represents a novel mechanism relevant to Alzheimer's disease therapy. Mol Psychiatry. 2018 Feb;23(2):211-221. doi: 10.1038/mp.2016.187. Epub 2016 Oct 25.
11. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1-2):81-4. doi:10.1016/S0304-3940(01)01872-9.
12. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008 Feb;62(2):149-53. doi: 10.1002/syn.20472.
13. Aracava Y, Pereira EFR, Maelicke A, Albuquerque EX. Memantine Blocks a7 * Nicotinic Acetylcholine Receptors More Potently Than N-Methyl-D-aspartate Receptors in Rat Hippocampal Neurons. J Pharmacol Exp Ther. 2005 Mar;312(3):1195-205. doi: 10.1124/jpet.104.077172. Epub 2004 Nov 2.
14. Madeira C, Alheira FV, Calcia MA, et al. Blood Levels of Glutamate and Glutamine in Recent Onset and Chronic Schizophrenia. Front Psychiatry. 2018 Dec 19;9:713. doi: 10.3389/fpsyt.2018.00713. eCollection 2018.
15. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020 Feb;19(1):15-33. doi: 10.1002/wps.20693.
16. Blacker CJ, Millischer V, Webb LM, et al. EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review. Mol Neuropsychiatry. 2020 Apr;5(Suppl 1):44-59. doi: 10.1159/000501885. Epub 2019 Jul 23.
17. Blacker CJ, Lewis CP, Frye MA, Veldic M. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. Psychiatry Res. 2017 Nov;257:327-337. doi: 10.1016/j.psychres.2017.07.059. Epub 2017 Jul 31.
18. Soeiro-de-Souza MG, Otaduy MCG, Machado-Vieira R, et al. Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Dec;3(12): 985-91. doi: 10.1016/j.bpsc.2018.02.007. Epub 2018 Mar 31
19. Inoshita M, Umehara H, Watanabe S, et al. Elevated peripheral blood glutamate levels in major depressive disorder. Neuropsychiatr Dis Treat. 2018 Apr 6;14:945-53. doi: 10.2147/NDT.S159855. eCollection 2018.
20. Shirayama Y, Takahashi M, Osone F, et al. Myo-inositol, Glutamate, and Glutamine in the Prefrontal Cortex, Hippocampus, and Amygdala in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Mar;2(2):196-204. doi: 10.1016/j.bpsc.2016.11.006. Epub 2016 Dec 2.
21. Averill LA, Abdallah CG, Fenton LR, et al. Early life stress and glutamate neurotransmission in major depressive disorder. Eur Neuropsychopharmacol. 2020 Jun;35:71-80. doi: 10.1016/j.euroneuro.2020.03.015. Epub 2020 May 15.
22. Karthik S, Sharma LP, Narayanaswamy JC. Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives. Neuropsychiatr Dis Treat. 2020 Apr 17;16:1003-13. doi: 10.2147/NDT.S211703. eCollection 2020.
23. Gavrilova SI. Memantine in treatment of Alzheimer's disease: 20 years of clinical use. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(6-2):10-8. (In Russ.).
24. Mikhailova NM. Memantine (akatinol) in the treatment of vascular dementia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015; 115(11-2):82-90. (In Russ.).
25. Bekker RA, Bykov YuV. Memantine: overview of its use in neurology. Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2017;(1): 34-43. (In Russ.).
26. Bekker RA, Bykov YuV. Memantine: possibilities and prospects of application in psychiatry (review of current data). Psikhiatriya i psikhofarmakoterapiya im. P.B. Gannushkina. 2016; (4):42-51. (In Russ.).
27. Amidfar M, Khiabany M, Kohi A, et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2017 Feb;42(1):44-50. doi: 10.1111/jcpt.12469. Epub 2016 Nov 3.
28. De Lucena D, Fernandes BS, Berk M, et al. Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine. J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry.
29. Fakhri A, Pakseresht S, Haghdoost MR, et al. Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. Acta Med Iran. 2016 Nov;54(11):696-703.
30. Mazinani R, Nejati S, Khodaei M. Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017 Jan;247:291-95. doi: 10.1016/j.psychres.2016.09.028. Epub 2016 Sep 21.
31. Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy M. The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, doubleblind, controlled, clinical trial. Adv Biomed Res. 2015 Sep 28;4:211. doi: 10.4103/2277-9175.166148. eCollection 2015.
32. Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy MR. The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a double blind, randomized, controlled trial. Actas Esp Psiquiatr. 2017 May;45(3):108-15. Epub 2017 May 1.
33. Rezaei F, Mohammad-karimi M, Seddighi S, et al. Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychopharmacol. 2013 Jun;33(3):336-42. doi: 10.1097/JCP.0b013e31828b50a7.
34. Sahraian A, Jahromi LR, Ghanizadeh A, Mowla A. Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Clin Psychopharmacol. 2017 Apr;37(2):246-49. doi: 10.1097/JCP000.0000000000651.
35. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial: Memantine augmentation of lamotrigine in bipolar depression. Bipolar Disord. 2012 Feb;14(1):64-70. doi: 10.1111/j.1399-5618.2011.00971.x.
36. Lee JG, Lee SW, Lee BJ, et al. Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study. Psychiatry Investig. 2012 Jun;9(2): 166-73. doi: 10.4306/pi.2012.9.2.166. Epub 2012 May 22.
37. Lieberman JA, Papadakis K, Csernansky J, et al. A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. Neuropsychopharmacology. 2009 Apr;34(5):1322-9. doi: 10.1038/npp.2008.200. Epub 2008 Nov 12.
38. Omranifard V, Shirzadi E, Samandari S, et al. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. J Res Med Sci. 2014 Jun;19(6):525-30.
39. Smith EG, Deligiannidis KM, Ulbricht CM, et al. Antidepressant Augmentation Using the N -Methyl- d -Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry. 2013 Oct;74(10):966-73. doi: 10.4088/JCP.12m08252.
40. Osadshii YuYu, Archakov DS, Tarakanova EA, Voblenko RA. A randomized, simple, blind, placebo-controlled trial of memantine as an adjunct to the treatment of negative symptoms in paranoid schizophrenia. Sovremennaya terapiya psikhicheskikh rasstroistv. 2015(3): 2-7. (In Russ.).
41. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1362-74. doi: 10.1016/j.pnpbp.2008.01.008. Epub 2008 Jan 17.
42. McCloud T, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015 Sep 29;(9): CD011611. doi: 10.1002/14651858.CD011611.pub2.
43. Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015 Sep 23;(9):CD011612. doi: 10.1002/14651858.CD011612.pub2.
44. Kishi T, Matsunaga S, Iwata N. A Meta-Analysis of Memantine for Depression. J Alzheimer's Dis. 2017;57(1):113-21. doi: 10.3233/JAD-161251.
45. Marinova Z, Chuang DM, Fineberg N. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder. Curr Neuropharmacol. 2017;15(7): 977-95. doi: 10.2174/1570159X15666170320104237.
46. Karthik S, Sharma LP, Narayanaswamy JC. Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives. Neuropsychiatr Dis Treat. 2020 Apr 17;16:1003-13. doi: 10.2147/NDT.S211703. eCollection 2020.
47. Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013 Feb;47(2):175-80. doi: 10.1016/j.jpsychires.2012.09.015. Epub 2012 Oct 9.
48. Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013 Aug; 228(4):633-40. doi: 10.1007/s00213-013-3067-z. Epub 2013 Mar 23.
49. Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Metaanalysis of randomized, placebo-controlled trials. J Psychiatr Res. 2013 Sep;47(9):1143-9. doi: 10.1016/j.jpsychires.2013.04.013. Epub 2013 May 18.
50. Zheng W, Li XH, Yang XH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018 Jan;48(1):72-81. doi: 10.1017/S0033291717001271. Epub 2017 May 22.
51. Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl). 2017 Jul;234(14):2113-25. doi: 10.1007/s00213-017-4616-7. Epub 2017 May 15.
52. Zheng W, Li XH, Yang XH, et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol Med. 2018 Jan;48(1): 72-81. doi: 10.1017/S0033291717001271. Epub 2017 May 22.
53. Singh SP, Singh V. Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia. CNS Drugs. 2011 Oct 1;25(10):859-85. doi: 10.2165/11586650-000000000-00000.
54. Zheng W, Zhu XM, Zhang QE, et al. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials. Schizophr Res. 2019 Jul;209:12-21. doi: 10.1016/j.schres.2019.05.019. Epub 2019 Jun 1.
55. Kishi T, Ikuta T, Oya K, et al. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. Int J Neuropsycho-pharmacol. 2018 Aug 1;21(8):748-757. doi: 10.1093/ijnp/pyy045.
56. Hassanpour F, Zarghami M, Mouodi S, et al. Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study. J Clin Psychopharmacol. Nov/Dec 2019;39(6):634-38. doi: 10.1097/JCP.0000000000001115.
57. Veerman SRT, Schulte PFJ, Deijen JB, de Haan L. Adjunctive memantine in clozapine-treated refractory schizophrenia: an openlabel 1-year extension study. Psychol Med. 2017 Jan;47(2):363-75. doi: 10.1017/S0033291716002476. Epub 2016 Oct 25.
58. Veerman SRT, Schulte PFJ, Smith JD, de Haan L. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med. 2016 Jul;46(9):1909-21. doi: 10.1017/S0033291716000398. Epub 2016 Apr 6.
59. Bhakta SG, Chou HH, Rana B, et al. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy. Psychopharmacology (Berl). 2016 Jun;233(12):2399-410. doi: 10.1007/s00213-016-4291-0. Epub 2016 Apr 13.
Review
For citations:
Romanov D.V., Yuzbashyan P.G. Memantine: procognitive and antinegative effects in mental illness (a literature review). Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):117-122. (In Russ.) https://doi.org/10.14412/2074-2711-2020-3-117-122
Views: 1120
Email this article 